SCHEMBL2939873

SCHEMBL2939873

CC(C)Sc1ccc(N)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 6/20 0.50
CYP3A4 P08684 5/20 0.50
TSHR P16473 2/20 0.50
MAPT P10636 3/20 0.42
MEN1 O00255 3/20 0.42
KMT2A Q03164 3/20 0.42
XDH P47989 1/20 0.42
TDP1 Q9NUW8 7/20 0.41
ALDH1A1 P00352 7/20 0.41
KDM4E B2RXH2 1/20 0.41
ACHE P22303 1/20 0.39
NPSR1 Q6W5P4 2/20 0.39
HSP90AA1 P07900 1/20 0.39
AGTR1 P30556 1/20 0.39
ATM Q13315 1/20 0.39
TP53 P04637 3/20 0.36
AR P10275 2/20 0.36
SERPINH1 P50454 2/20 0.36
ALOX15 P16050 3/20 0.35
PDE7A Q13946 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12112004 0.84 MAPK1 (0.50) MAPK1CYP3A4TSHRMAPTMEN1
SCHEMBL7297682 0.80 CYP3A4 (0.46) MAPK1CYP3A4TSHRMAPTMEN1
SCHEMBL7297677 0.80 MAPK1 (0.46) MAPK1CYP3A4TSHRMAPTMEN1
SCHEMBL12356893 0.79 LMNA (0.42) MAPK1CYP3A4TSHRMAPTMEN1
SCHEMBL21186075 0.78 XDH (0.44) MAPK1CYP3A4TSHRMEN1KMT2A
SCHEMBL8588330 0.78 AR (0.38) MAPK1CYP3A4TSHRMAPTMEN1
SCHEMBL11309197 0.77 MAPK1 (0.42) MAPK1CYP3A4TSHRMAPTMEN1
SCHEMBL14123913 0.77 CYP3A4 (0.42) MAPK1CYP3A4TSHRMAPTMEN1
SCHEMBL1454134 0.76 TDP1 (0.44) MAPK1TSHRMAPTMEN1KMT2A
SCHEMBL13111201 0.76 SLC6A4 (0.46) ALDH1A1SLC6A2SLC6A4SLC6A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11760775-B2 Steroids and protein-conjugates thereof REGENERON PHARMACEUTICALS, INC. 2023-09-19 US disclosed
US-11760775-B2 Steroids and protein-conjugates thereof REGENERON PHARMACEUTICALS, INC. 2023-09-19 US disclosed
WO-2023112764-A1 RELEASE LAYER-FORMING COMPOSITION AND RELEASE LAYER 日産化学株式会社 2023-06-22 WO disclosed
US-20210040144-A1 STEROIDS AND PROTEIN-CONJUGATES THEREOF REGENERON PHARMACEUTICALS, INC. 2021-02-11 US disclosed
US-10711032-B2 Steroids and protein-conjugates thereof REGENERON PHARMACEUTICALS, INC. (US) 2020-07-14 US disclosed
US-20180155389-A1 STEROIDS AND PROTEIN-CONJUGATES THEREOF REGENERON PHARMACEUTICALS, INC. 2018-06-07 US disclosed
US-20180155389-A1 STEROIDS AND PROTEIN-CONJUGATES THEREOF REGENERON PHARMACEUTICALS, INC. 2018-06-07 US disclosed
US-20170281641-A1 CYCLIC UREA COMPOUNDS AS TROPOMYOSIN-RELATED KINASE (TRK) iNHIBITORS GENZYME CORPORATION 2017-10-05 US disclosed
EP-3188729-A1 CYCLIC UREA COMPOUNDS AS TROPOMYOSIN-RELATED KINASE (TRK) INHIBITORS Genzyme Corporation (US) 2017-07-12 EP disclosed
EP-3163368-A1 LIQUID CRYSTAL DISPLAY ELEMENT JNC Corporation (JP) 2017-05-03 EP disclosed
US-20130225797-A1 OLIGONUCLEOTIDE AND USE THEREOF NATIONAL UNIVERSITY CORPORATION NAGOYA UNIVERSITY (JP) 2013-08-29 US disclosed
US-20130225797-A1 OLIGONUCLEOTIDE AND USE THEREOF NATIONAL UNIVERSITY CORPORATION NAGOYA UNIVERSITY (JP) 2013-08-29 US disclosed
US-7825115-B2 Cyclic urea compounds, preparation thereof and pharmaceutical use thereof as kinase inhibitors AVENTIS PHARMA S.A. (FR) 2010-11-02 US disclosed
EP-1599464-B1 NOVEL CYCLIC UREA DERIVATIVES, PREPARATION METHOD THEREOF AND PHARMACEUTICAL USE OF SAME AS KINASE INHIBITORS AVENTIS PHARMA SA (FR) 2010-09-22 EP disclosed
US-20080108654-A1 Cyclic Urea Compounds, Preparation Thereof and Pharmaceutical Use Thereof as Kinase Inhibitors AVENTIS PHARMA S.A. (FR) 2008-05-08 US disclosed
US-7354933-B2 Protein kinase inhibitors; antitumor agents; such as 5-methyl-1-quinol-4-ylmethyl-3-(4-trifluoromethanesulfonylphenyl)imidazolidine-2,4-dione trifluoroacetate AVENTIS PHARMA SA (FR) 2008-04-08 US disclosed
EP-1599464-A2 NOVEL CYCLIC UREA DERIVATIVES, PREPARATION METHOD THEREOF AND PHARMACEUTICAL USE OF SAME AS KINASE INHIBITORS Aventis Pharma S.A. (FR) 2005-11-30 EP disclosed
US-20040248884-A1 Novel cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors AVENTIS PHARMA S.A. (FR) 2004-12-09 US disclosed
WO-2004070050-A2 CYCLIC UREA DERIVATIVES, PREPARATION METHOD THEREOF AND PHARMACEUTICAL USE OF SAME AS KINASE INHIBITORS AVENTIS PHARMA S.A. (FR) 2004-08-19 WO disclosed
US-4303673-A N-Propionylsarcosineanilides, process for their preparation, and pharmaceutical compositions containing them A. NATTERMANN & CIE. GMBH (DE) 1981-12-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170281641-A1 CYCLIC UREA COMPOUNDS AS TROPOMYOSIN-RELATED KINASE (TRK) iNHIBITORS NGF, NTRK1, TK1 MAPK1 226/4885CYP3A4 4818/4885TSHR 294/4885
US-20080108654-A1 Cyclic Urea Compounds, Preparation Thereof and Pharmaceutical Use Thereof as Kinase Inhibitors PRKG1, PRKACA, CMPK1 MAPK1 53/4885CYP3A4 2988/4885TSHR 3517/4885
US-20180155389-A1 STEROIDS AND PROTEIN-CONJUGATES THEREOF SERPINA6, NR3C1, NR3C2 MAPK1 3841/4885CYP3A4 4146/4885TSHR 761/4885
US-20130225797-A1 OLIGONUCLEOTIDE AND USE THEREOF NOP2, HNRNPA2B1, NSUN2 MAPK1 2285/4885CYP3A4 2228/4885TSHR 1212/4885
US-20040248884-A1 Novel cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors PRKG1, PRKACA, PRKCA MAPK1 42/4885CYP3A4 2877/4885TSHR 3763/4885
US-10711032-B2 Steroids and protein-conjugates thereof SERPINA6, NR3C1, NR3C2 MAPK1 3841/4885CYP3A4 4146/4885TSHR 761/4885
US-20210040144-A1 STEROIDS AND PROTEIN-CONJUGATES THEREOF SERPINA6, NR3C1, NR3C2 MAPK1 3802/4885CYP3A4 4139/4885TSHR 809/4885
US-11760775-B2 Steroids and protein-conjugates thereof SERPINA6, NR3C1, NR3C2 MAPK1 3802/4885CYP3A4 4139/4885TSHR 809/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.